Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Adem Yesuf Dawed, Kaixin Zhou, Ewan Robert Pearson Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, Scotland, UK Abstract: Type 2 diabetes is one of the leading causes of morbidity and mortality, consuming a significant pr...
Saved in:
Main Authors: | Dawed AY (Author), Zhou K (Author), Pearson ER (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients
by: Sirajudeen Shaik Alavudeen, et al.
Published: (2020) -
Hypoglycemic agents and prognostic outcomes of chronic kidney disease patients with type 2 diabetes
by: Kyaw Kyaw Hoe, et al.
Published: (2023) -
Pharmacoeconomic analysis of use the oral hypoglycemic agents in patients with type 2 diabetes mellitus according to a real clinical practice
by: T. I. Ionova, et al.
Published: (2018) -
Adherence to Oral Hypoglycemic Agents in Hawaii
by: Deborah A. Taira, ScD, et al.
Published: (2005) -
Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
by: Yaochen Xie, et al.
Published: (2023)